bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
162 hedge funds and large institutions have $419M invested in bluebird bio in 2022 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 58 increasing their positions, 35 reducing their positions, and 24 closing their positions.
84% more capital invested
Capital invested by funds: $228M → $419M (+$191M)
66% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 35
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
26% more call options, than puts
Call options by funds: $8.09M | Put options by funds: $6.42M
7% more funds holding
Funds holding: 151 → 162 (+11)
0.4% more ownership
Funds ownership: 3.85% → 4.25% (+0.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$61.6M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$8.15M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$7.53M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.44M |
| 5 |
BlackRock
New York
|
+$6.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.4M |
| 2 |
Renaissance Technologies
New York
|
-$11.6M |
| 3 |
Millennium Management
New York
|
-$4.76M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.54M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.38M |
BLUE Hedge Fund Activity: Q3 2022 in Review
162 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2022, worth a combined $419M — up 84% from $228M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BLUE positions and 24 closed out — a net gain of 12 holders — while 58 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $61.6M. The largest seller was Wellington Management Group, cutting an estimated $33.4M.
- 162 institutional investors held bluebird bio (BLUE) as of Q3 2022, up from 151 in Q2 2022.
- Funds reported $419M of bluebird bio stock for Q3 2022, up 84% quarter-over-quarter.
- 36 funds opened new bluebird bio positions in Q3 2022 and 24 closed out, a net change of +12 holders.
- The largest bluebird bio buyer in Q3 2022 was State Street, an estimated $61.6M added.
- The largest bluebird bio seller in Q3 2022 was Wellington Management Group, an estimated $33.4M sold.
Based on aggregated 13F filings for Q3 2022.